|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||17.60 - 18.21|
|52 Week Range||2.35 - 23.91|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.83|
How have recent IBD Stock Of The Day picks fared? CrowdStrike IPO leads cybersecurity winners. Inphi stock has been strong. Amarin reversed while Amazon stock is right at its buy point.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Midatech Pharma PLC (NASDAQ: MTP ) shares ...
Amarin Corporation plc (AMRN) today announced the pricing of the underwritten public offering of 22,222,223 American Depositary Shares ("ADSs") at a price to the public of $18.00 per ADS. The gross proceeds of this offering are expected to be approximately $400.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Amarin.
BEDMINSTER, N.J. and DUBLIN, Ireland, July 17, 2019 -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced an underwritten public offering of.
Stocks don't generally move in gradual steady lines, either up or down. There is more of a tendency to jump, consolidate, then move again. The goal in swing trading is to capture the bulk of the jump and sidestep the consolidation or sideways movement. That's what we did with a recent swing trade in Amarin stock. Amarin Stock: Using A...
Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...
Biotech is a tough market to follow. Promising research avenues hit roadblocks, clinical trials can fail, and regulators can withhold approval. And all of that can happen to companies that frequently operate at a loss, with high initial overhead costs and a long road toward profitability.The rewards, however, are great. A new drug hitting the market, or news of a successful long-term trial, can bring in new investors and give a tremendous boost to a company’s shares. We’ve sorted through the data to find three biotechs that are making waves. These are mid- to large-cap firms, with new drugs in the pipeline or recently released, and high expectations for near-term returns. Amarin Corporation, Plc. (AMRN)Cardiac disease is a leading killer, and the American consumer is willing to pay a premium for cholesterol-reducing drugs of proven efficacy. Amarin has entered that niche with its sole product, Vascepa, a new drug based on Omega-3 fatty acids.You’ve heard of Omega-3, of course – it has been promoted for years as a dietary supplement for cardiovascular health. With Vascepa, Amarin has concentrated the active factors to create, not a supplement, but a hypertriglyceridemia drug for the specific treatment of high cholesterol. Vascepa was approved by the FDA in 2012, was promptly entered into the multi-year REDUCE-IT study, and in September 2018 Amarin announced the study results. In the controlled study of 8000 patients over six years, Vascepa showed significant results in preventing heart attacks. AMRN shares jumped from under $3 per share to over $15, and have held those gains.Now the company is looking to use its profits for expansion. Per Roth Capital’s Yasmeen Rahimi, “Amarin provided record revenue for the first half of 2019 for Vascepa, guided $380M-420M for 2019 and unveiled its plans to increase its U.S. sales team to about 800 in October 2019.” Rahimi sees this move as the beginning for Vascepa, heralding the drug’s conversion to a true money-maker for the Amarin. She gives the stock a $31 price target, suggesting an upside of 33%.Jefferies analyst Michael Yee agrees with the rosy outlook for Vascepa’s profit potential. He notes the “positive pre-announcement with upside Q2 sales beat and full-year guidance raise supporting the thesis of strong Vascepa launch and greater outlook and opportunity than consensus expectations.” Yee adds that he sees the stock moving higher to the upside on increases future sales. His price target, $30, implies a 29% potential for share price gains.Amarin has been doing well, on Vascepa’s strong reviews and success in the market. The stock has a unanimous analyst consensus of ‘Strong Buy,’ based on 6 buy ratings in the past three months. The average price target, $32, gives a 41% upside to the share price of $23.View AMRN Price Target & Analyst Ratings Detail Gilead Sciences, Inc. (GILD)Gilead is well-established in the pharma sector – it’s a major player on the American medical research scene, and holds a dominant position the HCV and HIV drug research segments. Casual consumers are more likely to encounter Gilead through its popular anti-viral drug Tamiflu, marketed as an OTC preventative and treatment for the flu.In recent development, Gilead has been moving filgotinib, a potential treatment for rheumatoid arthritis, forward in testing. Filgotinib is now if Phase III trials, and the company has announced that it will file a New Drug Application with the FDA – the next step in getting approval before marketing.Writing from RBC Capital, four-star analyst Brian Abrahams notes several factors that are boosting GILD stock. Filgotinib’s regulatory progress is prominent on the list. Abrahams also says that stock’s “valuation looks cheap and at a floor,” and points out the “strong balance sheet and solid dividend yield.”That last is an important point; most biotech firms do not pay any dividend, but Gilead initiated payments in 2015. The yield is now up to 3.68%, and payouts are $2.52 annualized, making it a strong incentive for investors. Abrahams’ price target on GILD, $91, indicates a 32% upside to the stock.Alethia Young, of Cantor Fitzgerald, has been following Gilead for several years, and had previously estimated that filgotinib would launch in the US in 2022 with initial sales up to $93 million. Citing the “positive" U.S. filing update,” she now believes that the timeline has moved up by at least one year and sees a potential approval in late 2020. She raised her price target on the stock to $88 to reflect her optimism.Gilead’s overall rating is a ‘Moderate Buy,’ based 13 buys, 5 holds, and 1 sell assigned during the past three months. The stock’s current share price is $68, and the average price target is $79; this gives GILD shares a 15% upside potential.View GILD Price Target & Analyst Ratings Detail Zogenix, Inc. (ZGNX)Like many smaller biotech research firms, Zogenix does not yet have a drug on the market. Unlike most such firms, however, Zogenix’ main research program is a reuse of a previously approved drug, fenfluramine. This was used in the past as a treatment for obesity; Zogenix has been researching its potential has a seizure treatment for children with the rare disease Dravet Syndrome. The studies have reached Phase III, and have shown some promise.The company’s stock took a hit, however, when the FDA last quarter ‘refused to file’ Zogenix’ application for fenfluramine as a new drug, branded Fintepla, for seizure treatment. ZGNX shares lost more than $10, and the company had to shift focus to bureaucratic streams.ZGNX got a boost last month, when the FDA reversed course. Regulators have said that they will permit the new drug application for Fintepla, and without additional preclinical toxicity data. According to Danielle Brill, pharma sector analyst from Piper Jaffray, this was the “best case scenario for Zogenix.” She says, “Although breakthrough therapy status was rescinded due to the recent approvals of two other drugs for Dravet Syndrome, expect an expedited review [with] approval and launch by Q2 of 2020. [Do] not expect the delay to have any meaningful impact on Fintepla's overall commercial potential.” She gives ZGNX shares a $64 price target, suggesting a 34% upside.Difei Yang, of Mizuho, also sees the FDA’s regulatory reversal as a win for Zogenix. She says, “A priority review is highly likely and the FDA's decision is a positive.” Yang bumped her price target up to $65, indicating confidence in a 36% upside.Zogenix’ upbeat regulatory outlook has given it support in the markets. Shares stand at $47, up $8 since the FDA decision. The average price target is $61, giving the stock a 28% upside potential. And like Amarin, the analysts are unanimous on ZGNX – 9 buy ratings give it a ‘Strong Buy’ consensus rating.View ZGNX Price Target and Analyst Ratings DetailVisit TipRanks’ Trending Stocks tool to see what else is hot in today’s markets.
Yesterday, Amarin (AMRN) revised its 2019 revenue guidance upwards from $350 million to $380 million–$420 million due to higher-than-anticipated demand for Vascepa in the first half of 2019.
It was a touch and go affair for the better part of yesterday's action, but by the time the closing bell rang, it was the bulls firmly in charge. The S&P 500 didn't make a new record high on Tuesday, but the close of 2,793.01 was 0.29% better than Monday's last trade, and a record close for the index.Source: Allan Ajifo via Wikimedia (Modified)Amarin (NASDAQ:AMRN) won the day, even if it didn't make a tremendously bullish impact on the overall market. Shares of the drug maker jumped more than 14% after the company upped its full-year revenue guidance after gauging early interest in its cardiovascular drug Vascepa. In a similar vein, Nio (NYSE:NIO) rallied nearly 8%. Although it did little to help the U.S. market, shareholders were well rewarded when other shareholders shrugged off the impact of a major recall and continued to right-price NIO shares following a brutal start to the year.At the other end of the spectrum, Chesapeake Energy (NYSE:CHK) was off more than 5%, hit mostly by falling and oil and gas prices that also undermined other energy names.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks That Should Be Every Young Investor's First Choice As for trading prospects though, the stock charts of Weyerhaeuser (NYSE:WY), Pfizer (NYSE:PFE) and CVS Health (NYSE:CVS) are your top bets headed into the pre-holiday sessions. Here's why, and what to look for next. Pfizer (PFE)Back on June 19, Pfizer was noted as a budding breakout candidate. It has just crossed above its 200-day moving average line, and although the volume behind the move was light, another effort to punch through a key resistance level around $43.30 was within reach. That move could inspire the needed volume.That happened that very same day. Although the move ultimately wavered a bit late last month, where and how it rekindled itself made the breakout effort even more convincing. Click to Enlarge * While once again on modest volume, PFE has moved back above the technical ceiling at $43.30, closing at its best close in months as of Tuesday. * The reversal point is telling. All it took was a kiss of the white 200-day moving average line on June 26 to prompt the sidelined bulls to jump in. * Zooming out to the weekly chart we can not only see a bullish MACD divergence, but that the most plausible target here is the ceiling clearly just above $46. CVS Health (CVS)CVS Health shares have been fighting a losing battle since 2017. Some of it was deserved; much of it wasn't. But, traders have been slow to reinflate the stock's price thus far, fearing there may be more would-be sellers waiting in the wings.The shape of the chart since April, however, suggests we may finally be transitioning from a net-bearish to a net-bullish environment. There's still much work to be done, but we're starting to see support and resistance exactly where and how we'd like too it take shape as the beginning of a rebound move. * 7 Restaurant Stocks to Put on Your Plate Click to Enlarge * On Monday, CVS stock clearly bumped into the gray 100-day moving average line, peeling back as a result. On Tuesday though, the purple 50-day moving average line held up as support. * It's evident on the daily chart, though much clearer on the weekly chart. That is, a major horizontal floor around $52 has taken shape. That has since been followed by a rising floor, marked in blue. * The make-or-break level from here is right around $55.55. That's where CVS shares peaked a few times in June, and where the 100-day moving average line will be later this week when it can be tested. Weyerhaeuser (WY)Finally, with the home-construction market presumably slowing down, it makes sense that shares of timber company Weyerhaeuser would be struggling. What if, however, the scope and depth of the slowdown wasn't nearly as troubling as most investors has assumed, and priced into WY stock?It's entirely possible that's what's happened, but is now being reversed as the market realizes the stock's undervalue. Recent gains have not only pushed shares back above one key technical hurdle, but have put Weyerhaeuser stock back within reach of another, even-bigger ceiling. Click to Enlarge * The recently crossed ceiling is the 200-day moving average line, plotted in white on both stock charts. It took two tries, but that resistance was cleared yesterday. * The next hurdle is an even bigger one, near $27.50, marked in yellow on both stock charts. That line connects all the key highs going back to early this year. * Although it would be a monumental event if cleared, once past $27.50, there's very little left to hold WY stock back … and certainly no prior ceiling or floors until the $34 area.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks That Should Be Every Young Investor's First Choice * 5 IPO Stocks to Buy -- According to Wall Street Analysts * The Top 10 Best Sectors in the Market for 2019 The post 3 Big Stock Charts for Wednesday: CVS Health, Pfizer and Weyerhaeuser appeared first on InvestorPlace.
Amarin stock popped Tuesday after the biotech company raised its full-year revenue outlook ahead of a potential supplemental approval for its high triglycerides treatment, Vascepa.
U.S. stocks end higher on Tuesday despite gloomy outlook for world economy that are driving bond yields lower.
It was a dull day in the markets, with it seemingly feeling like investors have already hit the exits for the holiday-shortened week. Remember, U.S. stock markets close at 1 p.m. ET on Wednesday and are closed on Thursday for the Fourth of July. Let's look at some top stock trades going into Wednesday. Top Stock Trades for Tomorrow 1: Nike Click to EnlargeNike (NYSE:NKE) was in the news Monday after the company decided to shelf a pair of Fourth of July kicks that some found offensive. From a stock perspective though, all we're concerned about is the price action.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNike stock slipped about 1% in response, as investors continue wondering if they'll get a better buying opportunity. * 7 Restaurant Stocks to Put on Your Plate Since April, Nike stock has not been able to generate much upside momentum. However, each little pullback in June was been met with buyers. For that to remain true, NKE stock needs to hold its 50-day moving average and uptrend support level (blue line).Below and we can get a pullback to the $80 to $81 area. While it will likely draw in buyers near that mark, a drop to the $77 to $78 area is possible if it fails as support. Top Stock Trades for Tomorrow 2: Amarin Click to EnlargeSolid guidance sent shares of Amarin (NASDAQ:AMRN) soaring on the day, up more than 15%. It's got the $23 level clear in its sights, and will trigger a big breakout if it's able to close above it.My fear here would be a gap-up over $23 that gets sold into. If that's the case, bears have a solid risk/reward should AMRN open above and then close below $23. Over $23 and bulls will maintain momentum. Top Stock Trades for Tomorrow 3: Goldman Sachs Click to EnlargeGoldman Sachs (NASDAQ:GS) gave a huge boost to its dividend last week. While other banks like JPMorgan (NYSE:JPM) and Bank of America (NYSE:BAC) raised their dividends, GS's put through a big increase of 47%.In any regard, the bank stock is -- unsurprisingly -- struggling to hold onto its gains. Above Monday's highs is the most encouraging, allowing GS to embark on even more upside. However, it needs to hold over the $198 to $200 level.Otherwise it will show that bulls have zero momentum right now. Top Stock Trades for Tomorrow 4: Nio Click to EnlargeNio (NASDAQ:NIO) has been ugly, but we have to give it credit, it sure is trying. Shares were up 7.5% at one point on Tuesday, as investors continue to try busting this one out of its nasty downtrend.Over $2.80-ish gets Nio above prior downtrend support and the 20-day moving average, two levels that acted as significant resistance last month. If it gets above these marks, the declining 50-day moving average and prior downtrend resistance mark near $3.50 are on the table.That's a lot of upside for aggressive bulls willing to speculate on the name. Let's see if it can breakout first, though. On the downside, keep watching $2.50 as support. Top Stock Trades for Tomorrow 5: Kroger Click to EnlargeThe last three weeks have been ugly for Kroger (NYSE:KR), and that may be putting it kindly. We highlighted the worry of closing below $23, so everyone bailing at sub-$21.50 has no excuse. We wrote: "$23 has proven to be a key level…Below that and KR could fall into no man's land, with multi-year lows lingering between $19 and $20." * 7 Stocks on Sale the Insiders Are Buying Let's see if KR stock can rally back to $23. If it does, let's see if this level acts as resistance or if Kroger can reclaim it and push through downtrend resistance. If it either can't rally back to $23 or if the stock continues to slide, let's see if support comes into play between $19 and $20.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best Stocks to Buy and Hold Forever * 10 Small-Cap Stocks That Look Like Bargains * 10 Names That Are Screaming Stocks to Buy The post 5 Top Stock Trades for Wednesday: NKE, AMRN, GS appeared first on InvestorPlace.
(Bloomberg) -- Amarin Corp.’s American depositary receipts surged to their highest intraday price since March 12 after the drugmaker said that its new heart pill was selling faster than projected and that it plans to double the size of its sales force.The company now expects 2019 revenue to be $380 million to $420 million, up from a May 1 prediction of $350 million. Amarin will also increase its sales force to approximately 800 people, it said in a statement Tuesday.The success of the heart drug, called Vascepa, had at one time made the Dublin-based company the subject of takeover speculation.“We have great confidence in our ability to successfully market and sell Vascepa in the U.S. on our own,” Chief Executive Officer John Thero said in an email to Bloomberg.The depositary receipts were up 13% to $21.79 at 1:01 p.m. in New York, after rising as much as 14%.Vascepa is approved for sale in the U.S. to lower patients’ triglyceride levels. Triglycerides are a type of fat in the blood, and too high a level can increase the risk of heart disease and stroke.The company has asked the U.S. Food and Drug Administration to let it market Vascepa as helping reduce the risk of cardiovascular events, following a successful clinical trial. The FDA’s decision is expected by late September.To contact the reporter on this story: Myah Ward in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Drew Armstrong at email@example.com, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Amarin news for Tuesday about its mid-year update for 2019 has AMRN stock heading higher.Source: AmarinAmarin (NASDAQ:AMRN) is increasing its revenue guidance for 2019 in its most recent update. This has the company now expecting revenue for the year to range from $380 million to $420 million. This is good news for AMRN stock as Wall Street is only looking for revenue of $364.78 million for the year.What Amarin news has the company so confident in its revenue outlook for 2019? The company says that it has already seen record revenue levels for the first half of the year. This includes it estimating revenue between $170 million and $174 million for the first half of the year. This is thanks to strong revenue performance in the company's second quarter of the year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Amarin news release notes that the company is also expecting great things from Vascepa. This is its drug that can "lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels."Amarin says that it is now filing a Supplemental New Drug Application for Vascepa. The company says that it believes the application of Vascepa is wider than it previously realized. If it gets approval from the U.S. Food & Drug Administration, it will allow the company to offer the drug to more customers. * 7 F-Rated Stocks to Sell for Summer "While Amarin remains optimistic that Vascepa will generate billions of dollars in revenue in the years to come, the history of other therapies for chronic conditions suggests that growth builds over multiple years, and thus, the company is not prepared to provide quantified guidance regarding revenue levels beyond 2019," the Amarin news release reads.AMRN stock was up 13% as of noon Tuesday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best Stocks to Buy and Hold Forever * 10 Small-Cap Stocks That Look Like Bargains * 10 Names That Are Screaming Stocks to Buy As of this writing, William White did not hold a position in any of the aforementioned securities.The post Amarin News: Why AMRN Stock Is Soaring Today appeared first on InvestorPlace.
The Dow Jones Industrial Average fluctuated Tuesday after White House trade adviser Peter Navarro said U.S. trade talks with China were heading in the right direction. rose on news that the world's biggest brewing company and maker of Budweiser beer is planning a Hong Kong listing of its Asian business that could raise around $10 billion. shares dipped after the sportswear company said it was pulling a planned sneaker release following a reported intervention from one of its key brand ambassadors.